Form 4: Kineta Executive's Holdings Converted Following TuHURA Biosciences Merger

Craig W. Philips, President and Secretary of Kineta, Inc., reported the disposition of all Kineta common stock and stock options as a result of Kineta's merger with TuHURA Biosciences, Inc., with Kineta shares converting into TuHURA common stock and certain options being canceled.

Summary

• Craig W. Philips, President and Secretary of Kineta, Inc., reported the disposition of all his direct and indirect beneficial ownership in Kineta common stock and stock options.
• This disposition occurred on June 30, 2025, pursuant to the Agreement and Plan of Merger dated December 11, 2024, as amended on May 5, 2025, between TuHURA Biosciences, Inc. and Kineta, Inc.
• Under the merger terms, each outstanding share of Kineta common stock was canceled and converted into the right to receive 0.185298 shares of TuHURA Common Stock.
• Kineta common stock holders are also entitled to a pro rata portion of 1,129,884 additional shares of TuHURA Common Stock, to be issued six months post-merger closing, subject to adjustment for losses.
• Additionally, Kineta common stock holders will receive a pro rata share of cash consideration from disposed legacy Kineta assets.
• All Kineta stock options outstanding immediately prior to the merger's effective time with an exercise price greater than $0.64 were canceled and extinguished for no consideration.

Sentiment

Score: 6

Explanation: The filing reports the expected completion of a merger, which is a significant corporate event. While some options were canceled for no value, the overall transaction provides Kineta shareholders with equity in the acquiring entity and potential future consideration, indicating a structured and anticipated outcome.

Positives

• Kineta shareholders, including Craig W. Philips, received shares in TuHURA Biosciences, Inc., providing continued equity participation in the combined entity.
• The merger provides for potential future consideration, including an additional 1,129,884 shares of TuHURA Common Stock and cash from disposed legacy Kineta assets.

Negatives

• Stock options with an exercise price greater than $0.64 were canceled and extinguished for no consideration, resulting in a loss of value for option holders.

Risks

• The issuance of 1,129,884 additional TuHURA Common Stock shares six months post-merger is subject to adjustment for losses incurred or accrued during that six-month period.
• The cash consideration is dependent on the successful receipt of disposed asset payments related to legacy Kineta assets, introducing uncertainty regarding the final cash amount.

Future Outlook

Kineta stockholders are expected to receive an additional 1,129,884 shares of TuHURA Common Stock approximately six months following the merger's closing, subject to potential adjustments for losses. Furthermore, they are entitled to a pro rata share of cash consideration derived from payments related to legacy Kineta assets that have been disposed of.

Industry Context

This filing reflects the completion of a specific corporate merger within the biotechnology or pharmaceutical sector, where Kineta, Inc. has been acquired by TuHURA Biosciences, Inc. Such mergers are common strategic moves for companies seeking to consolidate operations, expand pipelines, or achieve greater scale in the competitive life sciences industry.

Stakeholder Impact

• Shareholders (former Kineta): Received TuHURA Common Stock in exchange for their Kineta shares and are entitled to future contingent share and cash consideration.
• Option Holders (former Kineta): Those holding options with an exercise price greater than $0.64 experienced a complete loss of value for those options as they were canceled without consideration.

Next Steps

• Issuance of the pro rata portion of 1,129,884 shares of TuHURA Common Stock to former Kineta stockholders approximately six months following the merger closing.
• Distribution of pro rata cash consideration to former Kineta stockholders from disposed asset payments related to legacy Kineta assets.

Key Dates

Keywords

Kineta, TuHURA Biosciences, Merger, Form 4, Beneficial Ownership, Stock Options, Share Conversion, KANT, Corporate Transaction